The National Institute on Drug Abuse is offering a grant to support research on the effects of cannabinoids and the endocannabinoid system on HIV-induced inflammation and related impacts on nervous system function. This grant aims to fund basic science and preclinical projects that lead to a better understanding of the biological mechanisms involved. Applicants must possess expertise in both HIV/AIDS and addiction science. The closing date for submissions is March 11, 2020.
Opportunity ID: 322272
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | RFA-DA-20-022 |
Funding Opportunity Title: | Assessing the Effects of Cannabinoids on HIV-Induced Inflammation (R01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Grant |
Category of Funding Activity: | Education Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Nov 07, 2019 |
Last Updated Date: | Nov 07, 2019 |
Original Closing Date for Applications: | Mar 11, 2020 |
Current Closing Date for Applications: | Mar 11, 2020 |
Archive Date: | Apr 16, 2020 |
Estimated Total Program Funding: | – |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | County governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Independent school districts For profit organizations other than small businesses Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Public housing authorities/Indian housing authorities City or township governments Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | The purpose of this Funding Opportunity Announcement [FOA] is to encourage basic science and preclinical research to determine the biological mechanisms underlying the effects of cannabinoids and the endocannabinoid system on HIV-associated persistent inflammation and its consequent effects on nervous system function. Projects submitted in response to this FOA must include expertise and resources in both areas of HIV/AIDS and addiction science. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-20-022.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
There are no related documents on this grant.
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-F | Use for due dates on or after May 25, 2020 | PKG00259272 | Feb 11, 2020 | Mar 11, 2020 | View | |
FORMS-E | Use for due dates on or before May 24, 2020 | PKG00256457 | Feb 11, 2020 | May 24, 2020 | View |
Package 1
Mandatory forms
322272 RR_SF424_2_0-2.0.pdf
322272 PHS398_CoverPageSupplement_5_0-5.0.pdf
322272 RR_OtherProjectInfo_1_4-1.4.pdf
322272 PerformanceSite_2_0-2.0.pdf
322272 RR_KeyPersonExpanded_2_0-2.0.pdf
322272 PHS398_ResearchPlan_4_0-4.0.pdf
322272 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
322272 RR_Budget_1_4-1.4.pdf
322272 RR_SubawardBudget30_1_4-1.4.pdf
322272 PHS398_ModularBudget_1_2-1.2.pdf
322272 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
322272 RR_SF424_2_0-2.0.pdf
322272 PHS398_CoverPageSupplement_4_0-4.0.pdf
322272 RR_OtherProjectInfo_1_4-1.4.pdf
322272 PerformanceSite_2_0-2.0.pdf
322272 RR_KeyPersonExpanded_2_0-2.0.pdf
322272 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
322272 RR_Budget_1_4-1.4.pdf
322272 RR_SubawardBudget30_1_4-1.4.pdf
322272 PHS398_ModularBudget_1_2-1.2.pdf
322272 PHS_AssignmentRequestForm_2_0-2.0.pdf